- Home
- SUPN vs VRTS Comparison
SUPN vs VRTS Comparison
Compare SUPN & VRTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SUPN
- VRTS
- Stock Information
- Founded
- SUPN 2005
- VRTS 1988
- Country
- SUPN United States
- VRTS United States
- Employees
- SUPN N/A
- VRTS N/A
- Industry
- SUPN Biotechnology: Pharmaceutical Preparations
- VRTS Investment Managers
- Sector
- SUPN Health Care
- VRTS Finance
- Exchange
- SUPN Nasdaq
- VRTS Nasdaq
- Market Cap
- SUPN 2.1B
- VRTS 1.7B
- IPO Year
- SUPN 2012
- VRTS 1992
- Fundamental
- Price
- SUPN $37.74
- VRTS $209.64
- Analyst Decision
- SUPN Hold
- VRTS Hold
- Analyst Count
- SUPN 1
- VRTS 4
- Target Price
- SUPN $36.00
- VRTS $242.50
- AVG Volume (30 Days)
- SUPN 376.5K
- VRTS 34.6K
- Earning Date
- SUPN 02-25-2025
- VRTS 01-31-2025
- Dividend Yield
- SUPN N/A
- VRTS 4.28%
- EPS Growth
- SUPN 130.79
- VRTS N/A
- EPS
- SUPN 1.07
- VRTS 16.44
- Revenue
- SUPN $651,972,000.00
- VRTS $888,042,000.00
- Revenue This Year
- SUPN $7.82
- VRTS N/A
- Revenue Next Year
- SUPN N/A
- VRTS $5.32
- P/E Ratio
- SUPN $35.28
- VRTS $12.78
- Revenue Growth
- SUPN 6.79
- VRTS 7.12
- 52 Week Low
- SUPN $25.53
- VRTS $190.42
- 52 Week High
- SUPN $39.37
- VRTS $263.39
- Technical
- Relative Strength Index (RSI)
- SUPN 57.78
- VRTS 34.59
- Support Level
- SUPN $36.48
- VRTS $201.30
- Resistance Level
- SUPN $38.68
- VRTS $215.00
- Average True Range (ATR)
- SUPN 1.06
- VRTS 4.63
- MACD
- SUPN 0.09
- VRTS -0.43
- Stochastic Oscillator
- SUPN 68.46
- VRTS 36.80
About SUPN Supernus Pharmaceuticals Inc.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. The Company's diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.
About VRTS Virtus Investment Partners Inc.
Virtus Investment Partners Inc provides investment management and related services to individuals and institutions. Its retail products include open-end mutual funds, closed-end funds, exchange-traded funds, and variable insurance funds. Geographically, the activities are carried out through the region of the U.S. and the group generates revenue through investment management fees, distribution and service fees and administration and shareholder service fees.